Venous thromboembolism risk assessment among beta-thalassemia patients
BACKGROUND: Thromboembolic (TE) disorders are among the most common complications of beta-thalassemia. We designed this cross-sectional study to investigate the state of hypercoagulability and platelet activation in patients with beta-thalassemia. PATIENTS AND METHODS: Seventy-five patients diagnose...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Journal of Applied Hematology |
| Subjects: | |
| Online Access: | http://www.jahjournal.org/article.asp?issn=1658-5127;year=2023;volume=14;issue=3;spage=230;epage=235;aulast=Abo-Elwafa |
| _version_ | 1797649211167080448 |
|---|---|
| author | Hasnaa A Abo-Elwafa Laila M Youseff Ramadan A Mahmoud Mahmoud I Elbadry Ahmed Tawfeek Shereen P Aziz |
| author_facet | Hasnaa A Abo-Elwafa Laila M Youseff Ramadan A Mahmoud Mahmoud I Elbadry Ahmed Tawfeek Shereen P Aziz |
| author_sort | Hasnaa A Abo-Elwafa |
| collection | DOAJ |
| description | BACKGROUND: Thromboembolic (TE) disorders are among the most common complications of beta-thalassemia. We designed this cross-sectional study to investigate the state of hypercoagulability and platelet activation in patients with beta-thalassemia.
PATIENTS AND METHODS: Seventy-five patients diagnosed with beta-thalassemia by hemoglobin electrophoresis were divided into three groups of 25 patients each: Group I (thalassemia trait), Group II (thalassemia intermedia [TI]), and Group III (thalassemia major). In addition, 50 healthy individuals were included as controls. Both patients and control groups were subjected to clinical and laboratory assessment, which included measurement of protein C, anti-thrombin III, D-dimer, CD41, CD42, CD61, and CD62P, and detection of beta-chain mutations.
RESULTS: Levels of the platelet activation marker CD62P were significantly higher in beta-thalassemia patients (26.28 ± 18.01%) than in controls (4.78 ± 2.27%) (P < 0.001). The D-dimer level was significantly higher in beta-thalassemia patients (348.41 ± 571.01 ng/mL) than in controls (71.6 ± 39.61 ng/mL) (P < 0.001). Protein-C and AT-III levels were significantly lower in beta-thalassemia patients (71.45 ± 13.26%, 78.38 ± 15.32%) in comparison with controls (94.9 ± 13.03%, 96.52 ± 11.01%) (P < 0.001 and P < 0.001, respectively). TE disorders were found in 7/25 (9%) beta-thalassemia patients, especially in older and postsplenectomy patients. TE was most commonly found in beta-TI. Beta-chain mutations were found in all patients with TE disorders, especially compound heterozygous intervening sequence (IVS) (IVS1.6 [T > C]/IVS1.110 [G > A]).
CONCLUSION: Postsplenectomy teenagers and adults with beta-thalassemia with lower levels of natural anticoagulant in the blood, an increased level of D-dimer, and platelet activator factor had a significantly higher risk for TE than those with childhood beta-thalassemia and the control group. In comparison with other beta-thalassemia patients, TI with beta-chain mutations is more likely to develop TE. |
| first_indexed | 2024-03-11T15:42:59Z |
| format | Article |
| id | doaj.art-3ae3cdafcb8743d7a4ec9c6ed5e8e75f |
| institution | Directory Open Access Journal |
| issn | 1658-5127 |
| language | English |
| last_indexed | 2024-03-11T15:42:59Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Applied Hematology |
| spelling | doaj.art-3ae3cdafcb8743d7a4ec9c6ed5e8e75f2023-10-26T08:50:41ZengWolters Kluwer Medknow PublicationsJournal of Applied Hematology1658-51272023-01-0114323023510.4103/joah.joah_31_23Venous thromboembolism risk assessment among beta-thalassemia patientsHasnaa A Abo-ElwafaLaila M YouseffRamadan A MahmoudMahmoud I ElbadryAhmed TawfeekShereen P AzizBACKGROUND: Thromboembolic (TE) disorders are among the most common complications of beta-thalassemia. We designed this cross-sectional study to investigate the state of hypercoagulability and platelet activation in patients with beta-thalassemia. PATIENTS AND METHODS: Seventy-five patients diagnosed with beta-thalassemia by hemoglobin electrophoresis were divided into three groups of 25 patients each: Group I (thalassemia trait), Group II (thalassemia intermedia [TI]), and Group III (thalassemia major). In addition, 50 healthy individuals were included as controls. Both patients and control groups were subjected to clinical and laboratory assessment, which included measurement of protein C, anti-thrombin III, D-dimer, CD41, CD42, CD61, and CD62P, and detection of beta-chain mutations. RESULTS: Levels of the platelet activation marker CD62P were significantly higher in beta-thalassemia patients (26.28 ± 18.01%) than in controls (4.78 ± 2.27%) (P < 0.001). The D-dimer level was significantly higher in beta-thalassemia patients (348.41 ± 571.01 ng/mL) than in controls (71.6 ± 39.61 ng/mL) (P < 0.001). Protein-C and AT-III levels were significantly lower in beta-thalassemia patients (71.45 ± 13.26%, 78.38 ± 15.32%) in comparison with controls (94.9 ± 13.03%, 96.52 ± 11.01%) (P < 0.001 and P < 0.001, respectively). TE disorders were found in 7/25 (9%) beta-thalassemia patients, especially in older and postsplenectomy patients. TE was most commonly found in beta-TI. Beta-chain mutations were found in all patients with TE disorders, especially compound heterozygous intervening sequence (IVS) (IVS1.6 [T > C]/IVS1.110 [G > A]). CONCLUSION: Postsplenectomy teenagers and adults with beta-thalassemia with lower levels of natural anticoagulant in the blood, an increased level of D-dimer, and platelet activator factor had a significantly higher risk for TE than those with childhood beta-thalassemia and the control group. In comparison with other beta-thalassemia patients, TI with beta-chain mutations is more likely to develop TE.http://www.jahjournal.org/article.asp?issn=1658-5127;year=2023;volume=14;issue=3;spage=230;epage=235;aulast=Abo-Elwafabeta-chain mutationbeta-thalassemiad-dimernatural coagulation inhibitorsplatelet activation factor (cd62p) |
| spellingShingle | Hasnaa A Abo-Elwafa Laila M Youseff Ramadan A Mahmoud Mahmoud I Elbadry Ahmed Tawfeek Shereen P Aziz Venous thromboembolism risk assessment among beta-thalassemia patients Journal of Applied Hematology beta-chain mutation beta-thalassemia d-dimer natural coagulation inhibitors platelet activation factor (cd62p) |
| title | Venous thromboembolism risk assessment among beta-thalassemia patients |
| title_full | Venous thromboembolism risk assessment among beta-thalassemia patients |
| title_fullStr | Venous thromboembolism risk assessment among beta-thalassemia patients |
| title_full_unstemmed | Venous thromboembolism risk assessment among beta-thalassemia patients |
| title_short | Venous thromboembolism risk assessment among beta-thalassemia patients |
| title_sort | venous thromboembolism risk assessment among beta thalassemia patients |
| topic | beta-chain mutation beta-thalassemia d-dimer natural coagulation inhibitors platelet activation factor (cd62p) |
| url | http://www.jahjournal.org/article.asp?issn=1658-5127;year=2023;volume=14;issue=3;spage=230;epage=235;aulast=Abo-Elwafa |
| work_keys_str_mv | AT hasnaaaaboelwafa venousthromboembolismriskassessmentamongbetathalassemiapatients AT lailamyouseff venousthromboembolismriskassessmentamongbetathalassemiapatients AT ramadanamahmoud venousthromboembolismriskassessmentamongbetathalassemiapatients AT mahmoudielbadry venousthromboembolismriskassessmentamongbetathalassemiapatients AT ahmedtawfeek venousthromboembolismriskassessmentamongbetathalassemiapatients AT shereenpaziz venousthromboembolismriskassessmentamongbetathalassemiapatients |